Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – Combined results from two screening trials

SJ Skates; MH Greene; SS Buys; PL Mai; P Brown; M Piedmonte; G Rodriguez; JO Schorge; M Sherman; MB Daly; T Rutherford; WR Brewster; DM O'Malley; E Partridge; J Boggess; CW Drescher; C Isaacs; A Berchuck; S Domchek; SA Davidson; R Edwards; SA Elg; K Wakeley; KA Phillips; D Armstrong; I Horowitz; CJ Fabian; J Walker; PM Sluss; W Welch; L Minasian; NK Horick; CH Kasten; S Nayfield; D Alberts; DM Finkelstein; KH Lu

Journal article

Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk – Combined results from two screening trials

SJ Skates, MH Greene, SS Buys, PL Mai, P Brown, M Piedmonte, G Rodriguez, JO Schorge, M Sherman, MB Daly, T Rutherford, WR Brewster, DM O'Malley, E Partridge, J Boggess, CW Drescher, C Isaacs, A Berchuck, S Domchek, SA Davidson Show all

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2017

DOI: 10.1158/1078-0432.CCR-15-2750

Abstract

Purpose: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6- to 12-monthly CA125 > 35 U/mL. Experimental Design: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy. Specifically, serum CA125 q3 months, evaluated using a risk of ovarian cancer algorithm (ROCA), detected significant increases above..

View full abstract

University of Melbourne Researchers

Kelly Phillips Author

Related Projects (2)

REDUCING THE BURDEN OF BREAST CANCER FOR AUSTRALIAN WOMEN AND THEIR FAMILIES

PRECISION PREVENTION – FROM PRIORITY TO REALITY

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

The ROCA study was supported mainly by research grants/contracts from NCI to sites in the Cancer Genetics Network, the Ovarian SPORE program, and the Early Detection Research Network (CA078284 to D.M. Finkelstein, CA078134 to H. Anton-Culver, CA078164 to D. Bowen, CA078156 to S. Domchek, CA078148 to C. Griffin, CA078146 to C. Isaacs, CA078174 to G. Mineau, CA078157 to J. Schildkraut, CA078142 to L. Strong, HHSN2612007440000C to D.M. Finkelstein, CA083638 to R. Ozols, CA083591 to E. Partridge, CA086389 to H. Lynch). Fujirebio Diagnostics Inc supported the CGN study for one year after NCI funding ended. P.L. Mai and M. H. Greene were supported by the Intramural Research Program, NCI/NIH. The Gynecologic Oncology Group's study (GOG-0199) was supported by intramural research funds from the Clinical Genetics Branch and National Cancer Institute grants to the Gynecologic Oncology Group (GOG) Administrative Office and Tissue Bank (CA027469 to P. Di Saia), the GOG Statistical and Data Center (CA037517 to J. Blessing), and by NCI's Community Clinical Oncology Program (CCOP) grant (CA101165 to P. Di Saia). Participation by the investigators of the Australia and New Zealand Gynaecological Oncology Group (ANZGOG) is gratefully acknowledged. K.-A. Phillips is an Australian National Breast Cancer Foundation Fellow.